ClinicalTrials.gg
CompletedNCT00787085FACESUpdated Nov 7, 2008

The Significance of Funguria in Hospitalized Patients

An observational study in Urinary Tract Infections, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2008-11-07.

Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
919
Sex
All
01

Study summary

This investigation is a epidemiologic case-control study of the risk factors associated with nosocomial funguria (fungi in the urine).

Read the detailed description

A recent large multi-center national surveillance survey of almost 5000 nosocomial (hospital based) urine isolates from medical intensive care units demonstrated that fungi comprised nearly 40% of urine isolates. Little is known about distinguishing fungi that cause colonization from those causing infection.

The objective of this study is to define the epidemiology of nosocomial funguria and natural history of patients that develop funguria while hospitalized.

Patients who may have eligible for this study will be identified from microbiology laboratory specimens at the Harbor-UCLA Medical Center and Cedars-Sinai Medical Center.

02

Conditions studied

  • Urinary Tract Infections

Keywords

  • Funguria
  • Epidemiology
  • Urinary Tract Infections
03

In context

Urinary Tract Infections

779 studies on the registry are indexed under Urinary Tract Infections; 132 are open to participants now.

This study's enrollment of 919 is above the median of 200 across 193 observational studies indexed under Urinary Tract Infections.

Browse Urinary Tract Infections studies →

Lead sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is the lead sponsor of 67 studies on the registry; 1 is open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients hospitalized at the Harbor-UCLA Medical Center and Cedars-Sinai Medical Center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients hospitalized at least 12 hours of any age (\< 1 day to > 100 years of age) AND a urine or blood culture positive for fungi, OR urine culture negative for fungi (control group)

Exclusion criteria

Exclusion Criteria:

  • Patients already surveyed for funguria during current hospitalization and patients already being followed for recognized funguria
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
919 participants (actual)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Case

    Patients hospitalized with a urine or blood culture positive for fungi

  • Control

    Patients hospitalized with a urine culture negative for fungi

06

What researchers measure

Primary outcomes

  1. Funguria

    Time frame: Hospitalization day 0, 3, 7, 14, and every 7 days thereafter until hospital discharge or death

07

Study locations

2 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Harbor-UCLA Medical Center
    Torrance, California 90509, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 7, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00787085
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
First posted
Nov 7, 2008
Start date
Sep 2001
Primary completion
Feb 2006
Completion
Feb 2006
Last update
Nov 7, 2008

Study contacts

Loren G Miller, M.D., M.P.H.
principal investigator · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion